Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism.
Nowadays, cellular bioenergetics has become a central issue of investigation in cancer biology. Recently, the metabolic activity of the cancer cell has been shown to correlate with a proteomic index that informs of the relative mitochondrial activity of the cell. Within this new field of investigation, we report herein the production and characterization of high-affinity monoclonal antibodies against proteins of the "bioenergetic signature" of the cell. The use of recombinant proteins and antibodies against the mitochondrial beta-F1-ATPase and Hsp60 proteins and the enzymes of the glycolytic pathway glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase M2 in quantitative assays provide, for the first time, the actual amount of these proteins in normal and tumor surgical specimens of breast, lung, and esophagus. The application of this methodology affords a straightforward proteomic signature that quantifies the variable energetic demand of human tissues. Furthermore, the results show an unanticipated finding: tumors from different tissues and/or histological types have the same proteomic signature of energetic metabolism. Therefore, the results indicate that cancer abolishes the tissue-specific differences in the bioenergetic phenotype of mitochondria. Overall, the results support that energetic metabolism represents an additional hallmark of the phenotype of the cancer cell and a promising target for the treatment of diverse neoplasias.
Acebo
Paloma
P
Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, C.S.I.C.-U.A.M., Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, 28049 Madrid, Spain.
Giner
Daniel
D
Calvo
Piedad
P
Blanco-Rivero
Amaya
A
Ortega
Alvaro D
AD
Fernández
Pedro L
PL
Roncador
Giovanna
G
Fernández-Malavé
Edgar
E
Chamorro
Margarita
M
Cuezva
José M
JM
Science. 2006 Jun 16;312(5780):1650-3
16728594
Nature. 2008 Mar 13;452(7184):181-6
18337815
Nature. 2007 Jun 7;447(7145):741-4
17554312
Nature. 1976 Jun 24;261(5562):702-5
934318
Carcinogenesis. 2008 Nov;29(11):2053-61
18687667
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5992-7
15840712
Int J Cancer. 2008 Jul 15;123(2):476-483
18452174
Cancer Res. 2002 Nov 15;62(22):6674-81
12438266
Nat Genet. 2008 May;40(5):499-507
18443585
Cell. 2000 Jan 7;100(1):57-70
10647931
Carcinogenesis. 2006 May;27(5):925-35
16361271
Int J Colorectal Dis. 2008 Dec;23(12):1223-32
18769884
J Biol Chem. 2006 Jan 13;281(2):977-81
16263703
Cancer Res. 2005 Apr 15;65(8):3162-70
15833846
Curr Opin Biotechnol. 2006 Aug;17(4):415-21
16837184
Cancer Res. 2002 Jul 15;62(14):3909-13
12124317
PLoS One. 2006 Dec 20;1:e107
17205111
Cancer Cell. 2007 Jan;11(1):37-51
17222789
Nature. 2008 Mar 13;452(7184):230-3
18337823
Biochem J. 2004 Feb 15;378(Pt 1):17-20
14683524
Novartis Found Symp. 2001;240:251-60; discussion 260-4
11727934
Mol Cell. 1998 Feb;1(3):327-36
9660917
Cell Metab. 2008 Jan;7(1):11-20
18177721
Carcinogenesis. 2004 Jul;25(7):1157-63
14963017
J Natl Cancer Inst. 2006 Oct 18;98(20):1462-73
17047195
Trends Cell Biol. 2008 Apr;18(4):165-73
18296052
Cancer Res. 2006 Sep 15;66(18):8927-30
16982728
Cancer Res. 2007 Oct 1;67(19):9013-7
17909002
J Bioenerg Biomembr. 2007 Jun;39(3):259-65
17712532
Cell. 2003 Nov 26;115(5):629-40
14651853
J Clin Invest. 2007 Mar;117(3):719-29
17318262
Cancer Res. 2007 Apr 1;67(7):3364-70
17409446
Carcinogenesis. 2005 Dec;26(12):2095-104
16033770